Selexis names Yemi Onakunle as vp of strategic and market development

Former Diosynth and Lonza executive joins Swiss life science company

Geneva, Switzerland-based Selexis has hired Yemi Onakunle as vice president of strategic and market development. He will be responsible for expanding Selexis' presence in the drug discovery, next generation biologics and difficult-to-express protein markets.

Onakunle has more than 15 years' experience in drug manufacturing and cell line development. Prior to joining Selexis, he was director of commercial development at Diosynth RTP and associate director of business development at Lonza Custom Manufacturing.

More recently, Onakunle was head of sales and marketing at Bachem Americas, a contract manufacturing organisation focusing on peptides and complex organic molecules.

Onakunle is a member of the board of directors of VLP Biotech, a vaccine development company based in San Diego, CA and has been a business advisor to several biopharmaceutical and drug delivery companies.

You may also like

Research & Development

Faron links up with Selexis to progress development of cancer antibody

Under the agreement, Faron will have access to the Selexis SUREtechnology platform and SURE CHO-M cell line
Manufacturing

JHL Biotech and Selexis form biologic drug development alliance

Will provide seamless services from cell line development to cGMP manufacturing
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)

With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
Pharmaceutical

AIRPLAN S.A. showcases its dual strength in engineering and technology at CPHI 2025

AIRPLAN S.A. will once again participate in CPHI 2025, the world’s premier pharmaceutical event, taking place from October 28 to 30 in Frankfurt (Hall 9.0, booth B29)
Pharmaceutical

NEXTEN: Tomorrow's Tableting Innovations

A world première of the new IMA Active tablet presses
Research & Development

Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases

The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
Pharmaceutical

Global vaccine patents up 7% in a year despite US government's stance

Vaccine patent applications show sustained momentum after the COVID pandemic, with RNA vaccines now dominating the filings
Subscribe now